Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hinkle

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Eye & Contact Lens|May 17, 2006
Lid wiper epitheliopathy and dry eye symptomsDavid M Hinkle
Ocular Immunology and Inflammation|August 14, 2020
Re-assessing Evidence for Adverse Ocular Reactions Associated with Fluoroquinolones: Implications for Intracameral UseDavid M Hinkle
American Journal of Ophthalmology Case Reports|April 30, 2020
Transient mydriasis in toxoplasmosis retinochoroiditisBilal Rana, David M Hinkle
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 30, 2025
Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse EventsRaymond Rojas, David M Hinkle
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|February 28, 2026
Unique Importance of Vision Science Research and the National Eye InstituteShusheng Wang, David M Hinkle
Ophthalmic Plastic and Reconstructive Surgery|March 22, 2005
Conjunctival biopsy of anophthalmic socket in sarcoidosisDavid M Hinkle, Zeynel A Karcioglu
International Ophthalmology Clinics|April 23, 2008
Tubulointerstitial nephritis and uveitis syndromeDavid M Hinkle, C Stephen Foster
Ophthalmic Plastic and Reconstructive Surgery|May 9, 2013
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression"Gary E Borodic, David M Hinkle
Ophthalmic Plastic and Reconstructive Surgery|January 19, 2011
Drug-induced graves disease from CTLA-4 receptor suppressionGary Borodic, David M Hinkle, Yihong Cia
International Ophthalmology|March 16, 2013
Biologic agents in experimental autoimmune uveitisGian Paolo Giuliari, Ama Sadaka, David M Hinkle
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Eye & Contact Lens|May 17, 2006
Lid wiper epitheliopathy and dry eye symptomsDavid M Hinkle
Ocular Immunology and Inflammation|August 14, 2020
Re-assessing Evidence for Adverse Ocular Reactions Associated with Fluoroquinolones: Implications for Intracameral UseDavid M Hinkle
American Journal of Ophthalmology Case Reports|April 30, 2020
Transient mydriasis in toxoplasmosis retinochoroiditisBilal Rana, David M Hinkle
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 30, 2025
Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse EventsRaymond Rojas, David M Hinkle
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|February 28, 2026
Unique Importance of Vision Science Research and the National Eye InstituteShusheng Wang, David M Hinkle
Ophthalmic Plastic and Reconstructive Surgery|March 22, 2005
Conjunctival biopsy of anophthalmic socket in sarcoidosisDavid M Hinkle, Zeynel A Karcioglu
International Ophthalmology Clinics|April 23, 2008
Tubulointerstitial nephritis and uveitis syndromeDavid M Hinkle, C Stephen Foster
Ophthalmic Plastic and Reconstructive Surgery|May 9, 2013
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression"Gary E Borodic, David M Hinkle
Ophthalmic Plastic and Reconstructive Surgery|January 19, 2011
Drug-induced graves disease from CTLA-4 receptor suppressionGary Borodic, David M Hinkle, Yihong Cia
International Ophthalmology|March 16, 2013
Biologic agents in experimental autoimmune uveitisGian Paolo Giuliari, Ama Sadaka, David M Hinkle
Pageof 3